MedTrace Logo

Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

NCT01325181 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-05-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of chronic CSC.

Conditions

  • Chronic Central Serous Chorioretinopathy

Interventions

DRUG

Verteporfin

a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery

DRUG

ranibizumab

Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months

Sponsors & Collaborators

  • Novartis Korea Ltd.

    collaborator INDUSTRY

  • Jang Won Heo

    lead OTHER

Principal Investigators

  • Jang Won Heo, Professor · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • South Korea

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01325181 on ClinicalTrials.gov